Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: March 24, 2006
- Previous Holding: 17,561,959 ADRs
- New Holding: 17,600,190 ADRs
- Average Price: $53.01
This change resulted from a movement in the fund. Two directors, Dr J P Garnier and Dr T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4 R (1) (b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan as of March 24, 2006 (17,600,190).
- Confirm the average transaction price of $53.01 for the fund movement.
- Note that Directors Dr J P Garnier and Dr T Yamada have a potential interest in the fund shares.
- Understand that this filing does not contain financial performance data for the quarter.